Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session - Developmental and precision medicine

Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC

Date

22 Nov 2019

Session

Mini Oral session - Developmental and precision medicine

Presenters

Laura Mezquita

Citation

Annals of Oncology (2019) 30 (suppl_9): ix122-ix130. 10.1093/annonc/mdz431

Authors

L. Mezquita1, D. Planchard2, M. Dorta Suarez1, M. Aldea1, C. Naltet1, V. Lamberts2, M. Grecea3, P. Martin-Romano3, F. de Kievit4, C. Jovelet5, L. Lacroix5, J. Remon Masip1, P. Lavaud2, A. Gazzah6, C. Morris7, K. Howarth4, E. Green4, G. Vassal8, C. Massard3, B. Besse2

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Early Drug Development, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Research And Development, Inivata Ltd, 01223 - Cambridge/GB
  • 5 Translational Research Laboratory, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 6 Early Drug Development, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 Early Drug Development, Inivata Ltd, 01223 - Cambridge/GB
  • 8 Clinical Research, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings